Define the target
Provide the target identifier and optional sequence, isoform, mutation or PDB context.
All platforms
Therapeutics / Targeted Protein Degradation
From target to degrader candidates.
Describe the target, disease context and chemistry constraints. The pipeline runs a 14-stage design workflow — warhead, E3 ligase, linker, ternary complex, ubiquitination, degradation and developability — and returns a nominated candidate portfolio with stage-level evidence and uncertainty.
Use your existing Wellmatix account. Platform access is subject to approval.
Targeted Protein DegradationWorkflow overview
PROTACMolecular glueTargeted protein degradation
01Define the target
02Set chemistry and constraints
03Review the candidate portfolio
HOW IT WORKS
A focused path through your research.
From your inputs to evidence you can review.
Set chemistry and constraints
Optionally supply warhead or PROTAC SMILES, an E3 ligase strategy and candidate limits.
Review the candidate portfolio
Inspect the ranked candidates, scorecards, stage outputs and supporting evidence.
BEFORE YOU BEGIN
Bring your research context.
Prepare the information relevant to your workflow. The platform guides you through the required fields.
- Target identifier (gene symbol, UniProt or protein name)
- Disease, cell or tissue and desired phenotype context
- Optional warhead or PROTAC SMILES and E3 ligase strategy
- Modality route and candidate limits
WHAT YOU CAN EXPLORE
Outputs for your next decision.
- Ranked degrader candidate portfolio (PROTAC / molecular glue)
- Per-stage outputs with evidence, uncertainty and warnings
- Candidate scorecards with nomination status
Available outputs depend on the selected workflow and completed stages. Computational findings support expert review and experimental validation.
YOUR NEXT RESEARCH QUESTION
Explore Targeted Protein Degradation.
Sign in, request access if needed, and continue in your workspace.